Related Experiment Video
Updated: Apr 23, 2026

09:39
Mapping Dysfunctional Protein-Protein Interactions in Disease
Published on: October 24, 2025
1.1K
Toward an integrated pipeline for protein biomarker development
Andrei P Drabovich1, Eduardo Martínez-Morillo2, Eleftherios P Diamandis3
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Biochimica Et Biophysica Acta
|September 15, 2014
Summary
Developing protein biomarkers requires integrating basic, translational, and clinical research. This review details the protein biomarker development pipeline, focusing on mass spectrometry and complementary -omics approaches for rational discovery.
Area of Science:
- Biochemistry
- Proteomics
- Biomarker Discovery
Background:
- Protein biomarker development integrates basic, translational, and clinical research, presenting significant challenges.
- A unified pipeline is essential for rational discovery and to overcome past disappointments in the field.
Purpose of the Study:
- To provide a comprehensive review of the protein biomarker development pipeline.
- To critically assess individual phases including candidate identification, verification, and validation.
- To highlight the role of mass spectrometry and complementary -omics approaches.
Main Methods:
- Review of existing literature on protein biomarker development.
- Focus on mass spectrometry for protein identification and quantification.
- Discussion of complementary -omics strategies for biomarker candidate selection.
Main Results:
- Detailed examination of proteomic samples and protein-based clinical laboratory tests.
- Identification of limitations within the current biomarker development process.
- Critical assessment of each phase of the biomarker development pipeline.
Conclusions:
- Effective protein biomarker discovery necessitates integrating multidisciplinary efforts.
- Mass spectrometry and other -omics technologies are pivotal for advancing biomarker development.
- Addressing limitations is crucial for successful clinical translation of protein biomarkers.

